

# Fernando Bril

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/272844/publications.pdf>

Version: 2024-02-01

76  
papers

5,476  
citations

126907

33  
h-index

95266

68  
g-index

79  
all docs

79  
docs citations

79  
times ranked

6390  
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment of hyperglycemia not associated with NAFLD improvement in children with type 2 diabetes mellitus. <i>International Journal of Pediatrics and Adolescent Medicine</i> , 2022, 9, 83-88.	1.2	4
2	Noninvasive Diagnosis of Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis Using Machine Learning Methods: Comparative Study With Existing Quantitative Risk Scores. <i>JMIR Medical Informatics</i> , 2022, 10, e36997.	2.6	5
3	Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e4360-e4371.	3.6	6
4	Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes. <i>PLoS ONE</i> , 2021, 16, e0251449.	2.5	11
5	Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?. <i>Journal of Hepatology</i> , 2021, 75, 222-224.	3.7	167
6	PPAR $\alpha$ -induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH. <i>Liver International</i> , 2021, 41, 2659-2670.	3.9	51
7	Autoimmunity after Coronavirus Disease 2019 (COVID-19) Vaccine: A Case of Acquired Hemophilia A. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1674-1676.	3.4	24
8	Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: One or even several swallows do not make a summer. <i>Journal of Hepatology</i> , 2021, 75, 1256-1257.	3.7	15
9	What the New Definition of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Left Behind: Genetically Acquired Fatty Liver Disease (GAFLD). <i>EBioMedicine</i> , 2021, 72, 103584.	6.1	5
10	Reply to: "Comment on "Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?". <i>Journal of Hepatology</i> , 2021, 75, 996-997.	3.7	6
11	Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver. <i>Current Hypertension Reviews</i> , 2021, 17, 94-111.	0.9	9
12	Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening. <i>Diabetes Care</i> , 2021, 44, 399-406.	8.6	173
13	Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis. <i>Journal of Hepatology</i> , 2020, 72, 401-410.	3.7	40
14	Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2020, 43, 290-297.	8.6	113
15	Relationship between non-alcoholic fatty liver disease during pregnancy and abnormal glucose metabolism during and after pregnancy. <i>Journal of Investigative Medicine</i> , 2020, 68, 743-747.	1.6	13
16	747 ROLE OF INTERCELLULAR ADHESION MOLECULES IN THE SEVERITY OF LIVER DISEASE IN NONALCOHOLIC FATTY LIVER DISEASE (NAFLD). <i>Gastroenterology</i> , 2020, 158, S-1292-S-1293.	1.3	0
17	Nonalcoholic fatty liver disease in type 2 diabetes: awareness is the first step toward change. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 493-496.	1.5	3
18	Targeting pheochromocytoma/paraganglioma with polyamine inhibitors. <i>Metabolism: Clinical and Experimental</i> , 2020, 110, 154297.	3.4	11

#	ARTICLE	IF	CITATIONS
19	1461-P: Liver Fibrosis Is Common in Patients with Type 2 Diabetes Mellitus (T2DM) and Nonalcoholic Fatty Liver Disease (NAFLD). <i>Diabetes</i> , 2020, 69, 1461-P.	0.6	1
20	MON-644 Prevalence of Non-Alcoholic Fatty Liver Disease and Liver Fibrosis in Patients with Type 2 Diabetes Mellitus. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.2	0
21	1463-P: Relationship between Hepatic and Adipose Tissue Insulin Resistance with Liver Fibrosis in Patients with Type 2 Diabetes Mellitus (T2DM) and Nonalcoholic Fatty Liver Disease (NAFLD). <i>Diabetes</i> , 2020, 69, .	0.6	0
22	Central Nervous System Depressants and Risk of Hospitalization due to Community-Acquired Pneumonia in very Old Patients. <i>Current Drug Safety</i> , 2020, 15, 131-136.	0.6	1
23	MON-199 Targeting Pheochromocytoma/Paraganglioma with Polyamine Inhibitors. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.2	0
24	Simposio 9: Manejo diabetológico del paciente con hígado graso pensando en la pandemia. <i>Revista De La Sociedad Argentina De Diabetes</i> , 2020, 54, 40.	0.0	0
25	Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: A 36-month clinical trial. <i>Journal of Diabetes</i> , 2019, 11, 223-231.	1.8	26
26	Use of Plasma Fragments of Propeptides of Type III, V, and VI Procollagen for the Detection of Liver Fibrosis in Type 2 Diabetes. <i>Diabetes Care</i> , 2019, 42, 1348-1351.	8.6	37
27	Letter to the Editor: "Hepatic Insulin Extraction in NAFLD Is Related to Insulin Resistance Rather Than Liver Fat Content". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5249-5250.	3.6	2
28	Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial. <i>Diabetes Care</i> , 2019, 42, 1481-1488.	8.6	202
29	Emerging Circulating Biomarkers for the Diagnosis and Assessment of Treatment Responses in Patients with Hepatic Fat Accumulation, Nash and Liver Fibrosis. , 2019, , 423-448.		4
30	Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3327-3336.	3.6	68
31	Drug Development for Diabetes Mellitus: Beyond Hemoglobin A1c. , 2019, , 405-421.		0
32	Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2019, 70, 711-724.	7.3	305
33	Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 812-821.	4.4	117
34	Re: "Association Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis" by Mantovani et al. ( <i>Thyroid</i> 2018;28:1270-1284). <i>Thyroid</i> , 2019, 29, 452-452.	4.5	4
35	Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus. <i>Journal of Investigative Medicine</i> , 2019, 67, 303-311.	1.6	59
36	Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis. <i>Journal of Endocrinology</i> , 2019, 241, 293-305.	2.6	25

#	ARTICLE	IF	CITATIONS
37	223-OR: Pioglitazone Discontinuation in Patients with Nonalcoholic Steatohepatitis (NASH) Is Associated with Disease Recurrence. <i>Diabetes</i> , 2019, 68, 223-OR.	0.6	2
38	Basic Concepts in Insulin Resistance and Diabetes Treatment. , 2018, , 19-35.		3
39	Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 558-566.e2.	4.4	154
40	Use of a metabolomic approach to noninvasively diagnose nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1702-1709.	4.4	39
41	Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients. <i>Diabetes Care</i> , 2018, 41, 187-192.	8.6	37
42	Response to Comment on Bril et al. Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients. <i>Diabetes Care</i> 2018;41:187-192. <i>Diabetes Care</i> , 2018, 41, e137-e138.	8.6	2
43	Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2018, 315, E163-E173.	3.5	50
44	A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis. <i>Frontiers in Pharmacology</i> , 2018, 9, 752.	3.5	23
45	Role of Vitamin E for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients with T2DM: A Randomized, Controlled Trial. <i>Diabetes</i> , 2018, 67, 1223-P.	0.6	1
46	Utility of Fibroscan in Screening Overweight and Obese Children at Risk for Nonalcoholic Fatty Liver Disease. <i>Diabetes</i> , 2018, 67, .	0.6	1
47	Use of Plasma Metabolomics and Lipidomics for the Diagnosis of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes. <i>Diabetes</i> , 2018, 67, 1847-P.	0.6	4
48	Exenatide Treatment Improves Mitochondrial Metabolism and Hepatic Insulin Sensitivity in Mice with Nonalcoholic Steatohepatitis (NASH). <i>Diabetes</i> , 2018, 67, 1846-P.	0.6	0
49	Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. <i>Diabetes Care</i> , 2017, 40, 419-430.	8.6	256
50	Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis. <i>Annals of Internal Medicine</i> , 2017, 166, 230.	3.9	5
51	Concentration-dependent response to pioglitazone in nonalcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 56-61.	3.7	28
52	Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2950-2961.	3.6	66
53	Liver fat accumulation as a barometer of insulin responsiveness again points to adipose tissue as the culprit. <i>Hepatology</i> , 2017, 66, 296-297.	7.3	5
54	Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2017, 65, 1132-1144.	7.3	191

#	ARTICLE	IF	CITATIONS
55	Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies. <i>Trends in Endocrinology and Metabolism</i> , 2017, 28, 250-260.	7.1	228
56	Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus. <i>Annals of Internal Medicine</i> , 2016, 165, 305.	3.9	732
57	Plasma Thyroid Hormone Concentration is Associated with Hepatic Triglyceride Content in Patients with Type 2 Diabetes. <i>Journal of Investigative Medicine</i> , 2016, 64, 63-68.	1.6	26
58	Nonalcoholic Fatty Liver Disease. <i>Endocrinology and Metabolism Clinics of North America</i> , 2016, 45, 765-781.	3.2	107
59	Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2016, 39, 632-638.	8.6	108
60	Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 644-652.	3.6	127
61	A Systematic Approach to Assess the Burden of Drug Interactions in Adult Kidney Transplant Patients. <i>Current Drug Safety</i> , 2016, 11, 156-163.	0.6	17
62	Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients. <i>Liver International</i> , 2015, 35, 2139-2146.	3.9	169
63	Response to do ultrasonographic semiquantitative indices predict histological changes in NASH irrespective of steatosis extent?. <i>Liver International</i> , 2015, 35, 2341-2342.	3.9	1
64	High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2231-2238.	3.6	404
65	Cross-talk between branched-chain amino acids and hepatic mitochondria is compromised in nonalcoholic fatty liver disease. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2015, 309, E311-E319.	3.5	88
66	Relationship of vitamin D with insulin resistance and disease severity in non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2015, 62, 405-411.	3.7	98
67	The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2015, 61, 153-160.	7.3	156
68	Role of Insulin Resistance and Diabetes in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease. <i>Current Hepatology Reports</i> , 2014, 13, 159-170.	0.9	20
69	Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2014, 59, 2178-2187.	7.3	129
70	Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2014, 60, 167-174.	3.7	223
71	A validated liquid chromatography tandem mass spectrometry method for simultaneous determination of pioglitazone, hydroxypioglitazone, and ketopioglitazone in human plasma and its application to a clinical study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> . 2014. 969, 219-223.	2.3	12
72	Nonalcoholic Fatty Liver Disease: Current Issues and Novel Treatment Approaches. <i>Drugs</i> , 2013, 73, 1-14.	10.9	139

#	ARTICLE	IF	CITATIONS
73	Adverse drug reactions as a reason for admission to an internal medicine ward in Argentina. <i>International Journal of Risk and Safety in Medicine</i> , 2013, 25, 185-192.	0.6	18
74	The challenge of managing dyslipidemia in patients with nonalcoholic fatty liver disease. <i>Clinical Lipidology</i> , 2012, 7, 471-481.	0.4	23
75	Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2011, 54, 837-845.	7.3	74
76	Antimicrobial Agents-Associated with QT Interval Prolongation. <i>Current Drug Safety</i> , 2010, 5, 85-92.	0.6	29